The effect of royal jelly on prevention of postmenopausal bone loss.

The effect of royal jelly on prevention of postmenopausal bone loss. - Royal jelly and postmenopausal bone loss

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017629

Enrollment

Registered

2015-05-20

Start date

2015-05-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal bone loss

Interventions

Freeze dried law royal jelly 3,000mg/day (1,000mg as active ingredient) for 6 months. Placebo

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Healthy women (without risks of fracture) within 5 years of post-menopause.

Exclusion criteria

Exclusion criteria: Women who are allergic to royal jelly, women with asthma, women who have complications and medications that would affect bone metabolism, and women who need osteoporosis medication.

Design outcomes

Primary

Measure	Time frame
Bone mineral density, bone turnover markers	—

Countries

Japan

Contacts

Public ContactHiroshi Matsushita

Aichi Medical University School of Medicine Department of Obstetrics and Gynecology

hirosm@aichi-med-u.ac.jp0561-62-3311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026